Prescription Pricing for the People Act of 2025

FTC study of prescription drug middlemen

This bill would require the Federal Trade Commission to study pharmacy benefit managers and other drug supply middlemen. An interim report would be due 180 days after enactment. A full report would be due not later than 1 year after enactment. The reports would check if PBMs charge payers more than they reimburse pharmacies, steer patients to pharmacies they own, use unaffiliated pharmacies' data to gain advantage, or design formularies to favor higher-cost drugs net of rebates. The reports must also describe competition trends, legal or regulatory obstacles to enforcement, and planned FTC actions and recommendations. The bill would also require a separate FTC report on complaints about sole-source drug makers, including the number and nature of complaints, the FTC's ability to bring enforcement, and policy or legislative recommendations. The bill would define "appropriate committees" as the House and Senate Judiciary Committees and "Commission" as the Federal Trade Commission.